1.Derivation and Differentiation of Bone Marrow Mesenchymal Stem Cells from Osteoarthritis Patients.
Mamdooh GARI ; Haneen ALSEHLI ; Abdullah GARI ; Mohammed ABBAS ; Mohammed ALKAFF ; Mohammed ABUZINADAH ; Fatin AL-SAYES ; Mazin GARI ; Ashraf DALLOL ; Adel M ABUZENADAH ; Kalamegam GAUTHAMAN
Tissue Engineering and Regenerative Medicine 2016;13(6):732-739
Osteoarthritis (OA) of the knee is a degenerative joint disease caused by the progressive reduction of the articular cartilage surface that leads to reduced joint function. Cartilage degeneration occurs through gradual loss in extracellular matrix components including type II collagen and proteoglycan. Due to limited inherent self repair capacity of the cartilage, the use of cell-based therapies for articular cartilage regeneration is considered promising. Bone marrow mesenchymal stem cells (BM-MSCs) are multipotent cells and are highly capable of multilineage differentiation which render them valuable for regenerative medicine. In this study, BM-MSCs were isolated from OA patients and were characterized for MSC specific CD surface marker antigens using flowcytometry and their differentiation potential into adipocytes, osteocytes and chondrocytes were evaluated using histological and gene expression studies. BM-MSCs isolated from OA patients showed short spindle shaped morphology in culture and expressed positive MSC related CD markers. They also demonstrated positive staining with oil red O, alizarin red and alcian blue following differentiation into adipocytes, osteocytes and chondrocytes, respectively. In addition, chodrogenic related genes such as collagen type II alpha1, cartilage oligomeric matrix protein, fibromodulin, and SOX9 as well as osteocytic related genes such as alkaline phosphatase, core-binding factor alpha 1, osteopontin and RUNX2 runt-related transcription factor 2 were upregulated following chondrogenic and osteogenic differentiation respectively. We have successfully isolated and characterized BM-MSCs from OA patients. Although BM-MSCs has been widely studied and their potential in regenerative medicine is reported, the present study is the first report in our series of experiments on the BMSCs isolated from OA patients at King Abdulaziz University Hospital, Jeddah, Saudi Arabia.
Adipocytes
;
Adipogenesis
;
Alcian Blue
;
Alkaline Phosphatase
;
Antigens, Differentiation
;
Bone Marrow*
;
Cartilage
;
Cartilage Oligomeric Matrix Protein
;
Cartilage, Articular
;
Chondrocytes
;
Chondrogenesis
;
Collagen Type II
;
Core Binding Factors
;
Extracellular Matrix
;
Gene Expression
;
Humans
;
Joint Diseases
;
Joints
;
Knee
;
Mesenchymal Stromal Cells*
;
Osteoarthritis*
;
Osteocytes
;
Osteogenesis
;
Osteopontin
;
Proteoglycans
;
Regeneration
;
Regenerative Medicine
;
Saudi Arabia
;
Transcription Factors
2.The effect of antioxidant supplementation on dysmenorrhea and endometriosis-associated painful symptoms: a systematic review and meta-analysis of randomized clinical trials
Saeed BARADWAN ; Abdulrahim GARI ; Hussein SABBAN ; Majed Saeed ALSHAHRANI ; Khalid KHADAWARDI ; Ibtihal Abdulaziz BUKHARI ; Abdullah ALYOUSEF ; Ahmed ABU-ZAID
Obstetrics & Gynecology Science 2024;67(2):186-198
This study aimed to review randomized controlled trials (RCTs) investigating the effects of dietary antioxidant supplements on the severity of endometriosis-related pain symptoms. The PubMed/Medline, Scopus, and Web of Science databases were searched until April 2022. Additionally, we manually searched the reference lists. Endpoints were summarized as standardized mean difference (SMD) with 95% confidence intervals (CIs) in a random-effects model. The I2 statistic was used to assess heterogeneity. Ten RCTs were included in this meta-analysis. Overall, 10 studies were related to dysmenorrhea, four to dyspareunia, and four to pelvic pain. Antioxidants significantly reduced dysmenorrhea (SMD, -0.48; 95% CI, -0.82 to -0.13; I2=75.14%). In a subgroup analysis, a significant reduction of dysmenorrhea was observed only in a subset of trials that administered vitamin D (SMD, -0.59; 95% CI, -1.13 to -0.06; I2=69.59%) and melatonin (SMD, -1.40; 95% CI, -2.47 to -0.32; I2=79.15%). Meta-analysis results also suggested that antioxidant supplementation significantly improved pelvic pain (SMD, -1.51; 95% CI, -2.74 to -0.29; I2=93.96%), although they seem not to have a significant beneficial impact on the severity of dyspareunia. Dietary antioxidant supplementation seems to beneficially impact the severity of endometriosis-related dysmenorrhea (with an emphasis on vitamin D and melatonin) and pelvic pain. However, due to the relatively small sample size and high heterogeneity, the findings should be interpreted cautiously, and the importance of further well-designed clinical studies cannot be overstated.